Sangamo Therapeutics (SGMO) Equity Average (2016 - 2025)
Sangamo Therapeutics (SGMO) has disclosed Equity Average for 15 consecutive years, with -$4.0 million as the latest value for Q4 2025.
- For Q4 2025, Equity Average fell 112.96% year-over-year to -$4.0 million; the TTM value through Dec 2025 reached -$4.0 million, down 112.96%, while the annual FY2025 figure was $4.3 million, 91.95% down from the prior year.
- Equity Average hit -$4.0 million in Q4 2025 for Sangamo Therapeutics, down from $12.9 million in the prior quarter.
- Across five years, Equity Average topped out at $483.4 million in Q1 2021 and bottomed at -$4.0 million in Q4 2025.
- Average Equity Average over 5 years is $207.7 million, with a median of $234.5 million recorded in 2023.
- Year-over-year, Equity Average rose 16.88% in 2021 and then tumbled 112.96% in 2025.
- Sangamo Therapeutics' Equity Average stood at $390.7 million in 2021, then decreased by 22.68% to $302.1 million in 2022, then crashed by 63.95% to $108.9 million in 2023, then plummeted by 71.58% to $31.0 million in 2024, then plummeted by 112.96% to -$4.0 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at -$4.0 million, $12.9 million, and $12.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.